Back to top
more

Repligen (RGEN)

(Delayed Data from NSDQ)

$166.58 USD

166.58
341,269

+0.92 (0.56%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $166.53 -0.05 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for RGEN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Repligen Corporation falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 751 624 604 717 537
Receivables 124 116 117 71 44
Notes Receivable 0 0 0 0 0
Inventories 202 238 184 95 55
Other Current Assets 33 20 26 19 6
Total Current Assets 1,111 998 932 902 642
Net Property & Equipment 207 191 125 67 48
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 2 1 2 2 3
Intangibles 1,388 1,209 1,198 905 681
Deposits & Other Assets 1 1 1 1 0
Total Assets 2,824 2,525 2,358 1,903 1,400
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 20 28 36 17 11
Current Portion Long-Term Debt 69 285 255 244 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 51 71 76 53 33
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 13 14 0 0 0
Total Current Liabilities 158 404 375 319 48
Mortgages 0 0 0 0 0
Deferred Taxes/Income 40 23 33 27 30
Convertible Debt 510 0 0 0 233
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 18 55 97 1 2
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 853 614 608 374 340
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 1
Capital Surplus 1,569 1,547 1,572 1,461 1,068
Retained Earnings 439 397 194 66 6
Other Equity -37 -34 -17 2 -15
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 1,971 1,911 1,750 1,529 1,060
Total Liabilities & Shareholder's Equity 2,824 2,525 2,358 1,903 1,400
Total Common Equity 1,971 1,911 1,750 1,529 1,060
Shares Outstanding 55.80 55.50 55.20 52.60 52.00
Book Value Per Share 35.33 34.43 31.70 29.07 20.38

Fiscal Year End for Repligen Corporation falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 751 631 604 618
Receivables NA 124 106 120 133
Notes Receivable NA 0 0 0 0
Inventories NA 202 211 241 245
Other Current Assets NA 33 30 34 23
Total Current Assets NA 1,111 978 999 1,019
Net Property & Equipment NA 207 202 203 193
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 2 2 2 1
Intangibles NA 1,388 1,213 1,222 1,203
Deposits & Other Assets NA 1 1 2 1
Total Assets NA 2,824 2,514 2,549 2,538
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 20 19 24 26
Current Portion Long-Term Debt NA 69 286 286 285
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 51 43 45 58
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 13 13 16 28
Total Current Liabilities NA 158 363 374 405
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 40 14 22 22
Convertible Debt NA 510 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 18 48 43
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 853 526 578 598
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 1 1 1 1
Capital Surplus NA 1,569 1,567 1,561 1,545
Retained Earnings NA 439 464 446 426
Other Equity NA -37 -44 -37 -31
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 1,971 1,989 1,971 1,940
Total Liabilities & Shareholder's Equity NA 2,824 2,514 2,549 2,538
Total Common Equity 0 1,971 1,989 1,971 1,940
Shares Outstanding 55.80 55.80 55.80 55.60 55.60
Book Value Per Share 0.00 35.33 35.64 35.45 34.90